Primary (de novo) GBM has the highest incidence (accounting for 90% of all GBMs), affects older patients, and is most frequently associated with epidermal growth factor receptor (EGFR) overexpression (amplification of genes on chromosome 7), platelet-derived growth factor receptor (PDGFR) amplification (on chromosome 4), cyclin-dependent kinase inhibitor 2 A/B (CDKN2A/B) deletion (on chromosome 1), phosphate and tensin homologue (PTEN) mutations (on chromosome 10) and telomerase reverse transcriptase (TERT) promoter, among other factors [24,25]. The gene discussed is PTEN; the disease is glioblastoma.